Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in a Patient with Operable Breast Cancer

Overview

Journal Surg Today

Specialty General Surgery

Date 2008 Jul 10

PMID 18612781

Citations 8

Authors

Masato Hino

Muneaki Sano

Nobuaki Sato

Keiichi Homma

Affiliations

Soon will be listed here.

Abstract

Purpose: This study was undertaken to assess the feasibility of performing a sentinel lymph node biopsy (SLNB) for a patient with operable breast cancer after undergoing neoadjuvant chemotherapy (NAC).

Method: Between January 2002 and December 2003, women with primary breast cancer who had a breast tumor measuring larger than 3 cm in unilateral diameter were eligible for NAC. All patients who had completed NAC underwent lymphatic mapping with labeled (99m)Tc phytate on the day before surgery. Sentinel lymph node biopsy followed by a full axillary lymph node (AXLN) dissection (ALND) was performed in all patients. Sentinel lymph nodes (SLN) were sent for a frozen-section examination.

Results: The rate of SLN identification was 71%. Both the sensitivity and negative predictive value of SLNB were 100%. The false negative rate was 0%. When candidates for SLNB were restricted to patients with a breast tumor measuring less than 3 cm and clinically negative nodes after NAC, the rate of SLN identification increased to 93% from 71% while still maintaining the 0% false negative rate.

Conclusion: Sentinel lymph node biopsy after NAC is therefore considered to be a feasible and accurate method to predict the AXLN status in patients who have a breast tumor measuring less than 3 cm in unilateral diameter and a clinically negative AXLN status at the time of surgery after NAC.

Citing Articles

Magnetically guided surgery after primary systemic therapy for breast cancer: implications for enhanced axillary mapping.

Pantiora E, Eriksson S, Warnberg F, Karakatsanis A Br J Surg. 2024; 111(2).

PMID: 38325801 PMC: 10849829. DOI: 10.1093/bjs/znae008.

Outcomes of Sentinel Node Biopsy for Women with Breast Cancer After Neoadjuvant Therapy: Systematic Review and Meta-Analysis of Real-World Data.

Lin S, Vo N, Yen Y, Tam K Ann Surg Oncol. 2022; 29(5):3038-3049.

PMID: 35018590 DOI: 10.1245/s10434-021-11297-z.

Intraoperative molecular analysis of sentinel lymph nodes following neoadjuvant chemotherapy in patients with clinical node negative breast cancer: An institutional study.

Parada D, Pena K, Riu F, Aguilar A, Cohan S Mol Clin Oncol. 2016; 5(5):507-510.

PMID: 27882235 PMC: 5103850. DOI: 10.3892/mco.2016.1025.

Sentinel lymph node biopsy does not apply to all axillary lymph node-positive breast cancer patients after neoadjuvant chemotherapy.

Ge W, Yang B, Zuo W, Zheng G, Dai Y, Han C Thorac Cancer. 2016; 5(6):550-5.

PMID: 26767051 PMC: 4704328. DOI: 10.1111/1759-7714.12131.

Reoperative sentinel lymph node biopsy for ipsilateral breast tumor recurrence after previous axillary lymph node dissection: report of a case.

Hattori M, Nishimura S, Tada K, Koyama M, Akiyama F, Ito Y Surg Today. 2011; 41(2):247-50.

PMID: 21264762 DOI: 10.1007/s00595-009-4241-0.

References

Haid A, Tausch C, Lang A, Lutz J, Fritzsche H, Peschina W . Is sentinel lymph node biopsy reliable and indicated after preoperative chemotherapy in patients with breast carcinoma?. Cancer. 2001; 92(5):1080-4. View

Kuerer H, Newman L, Smith T, Ames F, Hunt K, Dhingra K . Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol. 1999; 17(2):460-9. DOI: 10.1200/JCO.1999.17.2.460. View

Sano M . President's Address: Minimally invasive treatment for patients with early breast cancer. Breast Cancer. 2004; 11(1):2-6. DOI: 10.1007/BF02967992. View

Fisher B, Jeong J, Anderson S, Bryant J, Fisher E, Wolmark N . Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation. N Engl J Med. 2002; 347(8):567-75. DOI: 10.1056/NEJMoa020128. View

Piato J, Barros A, Pincerato K, Sampaio A, Pinotti J . Sentinel lymph node biopsy in breast cancer after neoadjuvant chemotherapy. A pilot study. Eur J Surg Oncol. 2003; 29(2):118-20. DOI: 10.1053/ejso.2002.1349. View

Nason K, Anderson B, Byrd D, Dunnwald L, Eary J, Mankoff D . Increased false negative sentinel node biopsy rates after preoperative chemotherapy for invasive breast carcinoma. Cancer. 2001; 89(11):2187-94. View

Fisher E, Wang J, Bryant J, Fisher B, Mamounas E, Wolmark N . Pathobiology of preoperative chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel (NSABP) protocol B-18. Cancer. 2002; 95(4):681-95. DOI: 10.1002/cncr.10741. View

Veronesi U, Paganelli G, Viale G, Galimberti V, Luini A, Zurrida S . Sentinel lymph node biopsy and axillary dissection in breast cancer: results in a large series. J Natl Cancer Inst. 1999; 91(4):368-73. DOI: 10.1093/jnci/91.4.368. View

McMasters K, Tuttle T, Carlson D, Brown C, Noyes R, Glaser R . Sentinel lymph node biopsy for breast cancer: a suitable alternative to routine axillary dissection in multi-institutional practice when optimal technique is used. J Clin Oncol. 2000; 18(13):2560-6. DOI: 10.1200/JCO.2000.18.13.2560. View

10.

Cox C, Pendas S, Cox J, Joseph E, Shons A, Yeatman T . Guidelines for sentinel node biopsy and lymphatic mapping of patients with breast cancer. Ann Surg. 1998; 227(5):645-51; discussion 651-3. PMC: 1191339. DOI: 10.1097/00000658-199805000-00005. View

11.

Krag D, Weaver D, Ashikaga T, Moffat F, Klimberg V, Shriver C . The sentinel node in breast cancer--a multicenter validation study. N Engl J Med. 1998; 339(14):941-6. DOI: 10.1056/NEJM199810013391401. View

12.

Breslin T, Cohen L, Sahin A, Fleming J, Kuerer H, Newman L . Sentinel lymph node biopsy is accurate after neoadjuvant chemotherapy for breast cancer. J Clin Oncol. 2000; 18(20):3480-6. DOI: 10.1200/JCO.2000.18.20.3480. View

13.

Smith I, Heys S, Hutcheon A, Miller I, Payne S, Gilbert F . Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol. 2002; 20(6):1456-66. DOI: 10.1200/JCO.2002.20.6.1456. View

14.

Veronesi U, Paganelli G, Galimberti V, Viale G, Zurrida S, Bedoni M . Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph-nodes. Lancet. 1997; 349(9069):1864-7. DOI: 10.1016/S0140-6736(97)01004-0. View

15.

Giuliano A, Jones R, Brennan M, Statman R . Sentinel lymphadenectomy in breast cancer. J Clin Oncol. 1997; 15(6):2345-50. DOI: 10.1200/JCO.1997.15.6.2345. View

16.

Hack T, Cohen L, Katz J, Robson L, Goss P . Physical and psychological morbidity after axillary lymph node dissection for breast cancer. J Clin Oncol. 1999; 17(1):143-9. DOI: 10.1200/JCO.1999.17.1.143. View

17.

Veronesi U, Paganelli G, Viale G, Luini A, Zurrida S, Galimberti V . A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med. 2003; 349(6):546-53. DOI: 10.1056/NEJMoa012782. View

18.

Orr R . The impact of prophylactic axillary node dissection on breast cancer survival--a Bayesian meta-analysis. Ann Surg Oncol. 1999; 6(1):109-16. DOI: 10.1007/s10434-999-0109-1. View

19.

Giuliano A, Kirgan D, Guenther J, Morton D . Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg. 1994; 220(3):391-8; discussion 398-401. PMC: 1234400. DOI: 10.1097/00000658-199409000-00015. View

20.

Seymour M, Moskovic E, Walsh G, TROTT P, Smith I . Ultrasound assessment of residual abnormalities following primary chemotherapy for breast cancer. Br J Cancer. 1997; 76(3):371-6. PMC: 2224053. DOI: 10.1038/bjc.1997.392. View